Biogen's last-ditch pitch for an injunction to protect Tecfidera is denied, paving way for Mylan generic

After a long and drawn-out court fight, it seems all but inevitable that a generic version of Biogen’s blockbuster Tecfidera will hit the market sometime later this year.

The Cambridge, MA-based company’s last-ditch efforts to stop a Mylan generic fell flat Thursday, as a federal appellate court denied Biogen an injunction in a ruling last month invalidating Biogen’s ‘514 patent for the multiple sclerosis drug. Had the patent not been wiped out, Biogen would have delayed generic competition until 2028.